L. Kramer

发表

Lecanemab in Early Alzheimer's Disease.

R. Bateman, B. Vellas, C. V. van Dyck, 2022, The New England journal of medicine.

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

R. Bateman, E. McDade, J. Cummings, 2022, Alzheimer's research & therapy.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

D. Berry, J. Cummings, L. Lannfelt, 2020, Alzheimer's Research & Therapy.

The β-Secretase BACE1 in Alzheimer’s Disease

B. de Strooper, H. Hampel, S. Lista, 2020, Biological Psychiatry.

The b-Secretase BACE1 in Alzheimer’s Disease

J. Hardy, B. Strooper, H. Hampel, 2020 .

Alzheimer's disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla)

Patrick R Hof, Chet C Sherwood, Mary Ann Raghanti, 2013, The Journal of comparative neurology.

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

L. Honig, J. Barakos, C. Swanson, 2023, Alzheimer's & dementia.

Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease

D. Berry, Scott Berry, C. Swanson, 2022, Alzheimer's research & therapy.

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease

Keith A. Johnson, R. Sperling, P. Aisen, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Time to exceed pre‐randomization monthly seizure count for perampanel in participants with primary generalized tonic–clonic seizures: A potential clinical end point

Wesley T. Kerr, J. French, C. Brandt, 2022, Epilepsia.

TREATMENT OF EARLY AD SUBJECTS WITH BAN2401, AN ANTI-Aβ PROTOFIBRIL MONOCLONAL ANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE

L. Lannfelt, R. Lai, J. Luthman, 2018, Alzheimer's & Dementia.

Plasma Aβ 42:40 ratio tracks with changes in brain amyloid PET SUVr in the core and open label extension of the phase 2 proof of concept study ban2401‐g000‐201 following treatment with lecanemab in subjects with early Alzheimer’s disease

M. Hodgkinson, M. Irizarry, D. Verbel, 2021, Alzheimer's & Dementia.

Lecanemab for Patients With Early Alzheimer Disease

S. Berry, D. Berry, C. Swanson, 2023, JAMA network open.

Development of perampanel in epilepsy

A. Satlin, A. Laurenza, L. Kramer, 2013, Acta neurologica Scandinavica. Supplementum.

Perampanel for adjunctive treatment of partial‐onset seizures: A pooled dose–response analysis of phase III studies

E. Ben-Menachem, P. Kwan, J. Shih, 2014, Epilepsia.

AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial)

Keith A. Johnson, R. Sperling, P. Aisen, 2020, Alzheimer's & Dementia.

Lecanemab, an anti-Aβ protofibril antibody: Updated data from a randomized, double-blind phase 2B proof of concept clinical trial and open-label extension in early Alzheimer's disease

M. Hodgkinson, J. Kaplow, C. Swanson, 2021, Journal of the Neurological Sciences.